-
-
-
Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment
-
-
- This issue chosen by the Editor of Intestinal Research is Asian consensus on tuberculosis infection in patients with inflammatory bowel disease (IBD) receiving anti-tumor necrosis factor (anti-TNF) therapy.
Because anti-TNF therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in this region. Twenty-three consensus statements were discussed by 211 IBD specialists from 9 Asian countries.
Part 1 comprised "risk of TB infection during anti-TNF therapy" and "screening for TB infection before anti-TNF therapy". Part 2 comprised "management of latent TB before anti-TNF therapy", "monitoring during anti-TNF therapy", and "management of an active TB infection after anti-TNF therapy".
Read about these consensus statements to reduce the morbidity and mortality related to TB infections in patients with IBD receiving anti-TNF treatment.
In addition to this article, read other articles about TB infections in patients with IBD.
Best regards,
- Related article
-
- 1. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment
Park DI, Hisamatsu T, Chen M, Ng SC, Ooi CJ, Wei SC, Banerjee R, Hilmi IN, Jeen YT, Han DS, Kim HJ, Ran Z, Wu K, Qian J, Hu PJ, Matsuoka K, Andoh A, Suzuki Y, Sugano K, Watanabe M, Hibi T, Puri AS, Yang SK. Intest Res 2018;16(1):4-16
https://doi.org/10.5217/ir.2018.16.1.4 - 2. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management
Park DI, Hisamatsu T, Chen M, Ng SC, Ooi CJ, Wei SC, Banerjee R, Hilmi IN, Jeen YT, Han DS, Kim HJ, Ran Z, Wu K, Qian J, Hu PJ, Matsuoka K, Andoh A, Suzuki Y, Sugano K, Watanabe M, Hibi T, Puri AS, Yang SK. Intest Res 2018;16(1):17-25
https://doi.org/10.5217/ir.2018.16.1.17 - 3. Clinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel disease
Lee JW, Choi CH, Park JH, Kim JW, Kang SB, Koo JS, Kim YH, Kim YS, Joo YE, , Chang SK. Intest Res 2016;14(2):146-151
https://doi.org/10.5217/ir.2016.14.2.146 - 4. Diagnosis and Treatment of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Diseases due to Initiation of Anti-Tumor Necrosis Factor Therapy
Shim TS . Intest Res 2014;12(1):12-19
https://doi.org/10.5217/ir.2014.12.1.12
